Breast cancer remains one of the most prevalent and deadly cancers among women worldwide, with early detection being critical to improving patient outcomes. Mammograms, the frontline imaging tool for breast cancer screening, have traditionally been interpreted manually or with rudimentary computer assistance, primarily focusing on visible abnormalities. However, emerging deep learning (DL) techniques promise to decode subtler imaging biomarkers—patterns and features within the breast tissue that may signal an increased risk of cancer years before clinical manifestation.

The current study centers on Mirai, a cutting-edge deep learning model trained exclusively on mammographic images to predict breast cancer risk. Mirai harnesses complex patterns that escape conventional radiological assessment, extracting probabilistic risk estimations from raw imaging data. While Mirai has already demonstrated impressive predictive power, the researchers posited that integrating genetic data could elevate this approach. Specifically, they explored the incorporation of polygenic risk scores (PRS), which aggregate the effect of thousands of common genetic variants associated with breast cancer susceptibility.

Polygenic risk scores have emerged as a powerful genomic tool that quantify inherited cancer predisposition across a continuum of risk rather than relying on rare high-penetrance mutations alone. PRS capture immense genetic complexity and have been validated for breast cancer risk stratification in diverse populations. However, PRS alone do not provide spatial or temporal resolution about tissue changes, which imaging biomarkers uniquely offer. The fusion of these two complementary risk layers—image-based phenotypic risk and genotype-based inherited risk—conceptually promises a paradigm shift towards holistic, multi-modal risk prediction.

In this rigorous evaluation, the research team utilized a large, well-characterized cohort with comprehensive mammographic imaging and genotype data. They applied Mirai to mammograms to generate personalized risk estimates, then integrated these with independently derived polygenic risk scores calculated from participants’ genome-wide variant data. The integration was designed to assess additive or synergistic improvements in prediction accuracy, calibrated risk stratification, and clinical applicability.

The results, published in the British Journal of Cancer, confirm that while Mirai’s imaging-only predictions are robust, the addition of polygenic risk scores enhances discriminatory ability modestly but consistently. This finding is critical because even incremental gains in early risk prediction translate to significant clinical impact in terms of screening intervals, preventive interventions, and resource allocation. The combined model showed superior stratification of individuals into meaningful risk categories compared to either modality alone.

A key technical insight underpinning this success lies in the complementary nature of data sources. Mammographic images encode phenotypic manifestations of risk that can result from hormonal, environmental, or aging-related influences, while polygenic risk scores reflect inherited susceptibility embedded within the genome. By applying advanced probabilistic modeling techniques, the researchers effectively merged heterogeneous data to produce a unified risk estimate with enhanced predictive confidence.

Moreover, the study delved into how the integrated model performs across subpopulations, including different age groups, breast density categories, and ancestral backgrounds. Encouragingly, the combined approach maintained its performance robustness, suggesting broad clinical utility. This addresses a persistent challenge in breast cancer risk prediction—ensuring equitable accuracy across population strata commonly underrepresented in genomic and imaging datasets.

The implications of integrating AI-driven imaging biomarkers with polygenic risk extend well beyond risk estimation. The framework sets a precedent for multi-modal precision medicine where imaging, genomics, and potentially other data types like blood biomarkers or lifestyle factors can be cohesively analyzed. This could revolutionize how screening programs are personalized, enabling dynamic adjustment of screening frequency and modality based on evolving composite risk profiles.

Nevertheless, the authors acknowledge limitations and important areas for future investigation. The study cohort, while large, primarily represented populations of European ancestry, necessitating validation in more diverse ethnic groups given variability in genetic architecture. Additionally, the incremental performance boost, though statistically significant, underscores the need for further refinement in fusion algorithms and exploration of additional biomarkers to maximize predictive gains.

The integration of deep learning mammographic models with polygenic risk scores exemplifies a transformative trend in oncology—leveraging the power of AI and genomics to move beyond binary disease classification towards nuanced, individualized risk landscapes. It heralds a future where women can receive personalized breast cancer screening schedules tailored not only to imaging findings but also to their unique genetic risk, enabling earlier interventions that could substantially reduce morbidity and mortality.

This study lays a crucial foundation for clinical translation, emphasizing the potential for integrated multi-modal risk prediction tools to become standard components of breast cancer prevention strategies. As computational and genomic technologies continue to advance, we can expect progressively refined models that incorporate even deeper layers of biological complexity, from tumor microenvironment imaging to epigenetic modifications.

Importantly, this research underscores the need for collaborative efforts bridging radiology, genetics, data science, and clinical oncology to develop, validate, and implement these sophisticated predictive models in real-world healthcare settings. Ensuring interpretability, ease of integration into clinical workflows, and equitable access will be paramount challenges as these tools transition from research to practice.

Ultimately, the combination of imaging biomarkers and polygenic risk scores represents a monumental leap towards personalized oncology. It exemplifies how contemporary medicine harnesses massive data, sophisticated algorithms, and biological insights to tackle one of the most pressing health issues faced by women worldwide. The promise of AI-augmented genomic medicine in breast cancer risk prediction is not just to improve statistics but to transform lives through earlier, wiser, and more individualized care.

As breast cancer prevention enters this new era, the synergy between human biology and machine intelligence will redefine what is possible in early detection and precision intervention. This landmark study by Azam et al. thus serves as both a scientific milestone and a beacon guiding future exploration at the nexus of medical imaging and genomics, sparking renewed hope in the global fight against breast cancer.

Subject of Research: Breast cancer risk prediction using deep learning mammographic models combined with polygenic risk scores.

Article Title: Performance of an image-only deep learning breast cancer risk model with the addition of a polygenic risk score.

Article References:
Azam, S., Lamb, L.R., Eliassen, A.H. et al. Performance of an image-only deep learning breast cancer risk model with the addition of a polygenic risk score. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03415-z

Image Credits: AI Generated

DOI: 06 April 2026

The trial, which has secured $16 million in funding from the Patient-Centered Outcomes Research Institute (PCORI), represents the first large-scale randomized effort in the U.S. to systematically investigate how AI can support radiologists in interpreting mammograms. By leveraging advanced AI algorithms integrated through clinical workflows, this study aims to enhance early cancer detection, simultaneously reducing false positive rates and unnecessary patient recalls—problems that frequently plague conventional mammography screening programs, leading to patient anxiety and increased healthcare costs.

PRISM involves a collaborative network spanning seven leading academic institutions across six states—including UCLA, UC Davis, Boston Medical Center, UC San Diego, Sylvester Comprehensive Cancer Center, University of Washington-Fred Hutchinson Cancer Center, and University of Wisconsin-Madison. These centers will interpret hundreds of thousands of mammograms using a randomized approach where images are either assessed by radiologists unaided or with the decision support of an FDA-cleared AI platform known as Transpara by ScreenPoint Medical, seamlessly integrated into clinical workflows via the Aidoc aiOS platform.

The AI system in question operates by analyzing mammographic images using deep convolutional neural networks optimized for breast tissue characterization. This technology quantifies risk scores indicating the likelihood of malignancy, thereby providing radiologists with an AI-derived second opinion. Importantly, despite the assistance offered by AI, participating radiologists retain full control over final diagnostic decisions, ensuring clinical expertise remains paramount.

Jose Net, M.D., Director of Breast Imaging Services at Sylvester and co-principal investigator of the trial, emphasizes the critical balance sought in this research. “Our objective is not to replace the radiologist but to understand precisely how AI tools can augment diagnostic accuracy in a meaningful and patient-centered way,” Dr. Net remarks. The trial’s patient-first design reflects this ethos by maintaining existing screening protocols at each center, without any alteration in the patient experience or additional procedural burden.

The scientific premise for this trial arises from the challenges associated with mammographic screening. While mammography remains the cornerstone for early breast cancer detection and has demonstrably reduced mortality rates, limitations such as false positives—which generate unnecessary follow-up tests and psychological distress—and false negatives, where cancers go undetected, necessitate improvements in interpretation methodologies. AI holds transformative potential, but its actual performance in clinical environments has remained under-explored until now.

With regard to study design, mammograms will be randomized upon acquisition, ensuring that some images are read with AI assistance and others are interpreted solely by radiologists in the standard of care arm. This randomization enables robust comparative effectiveness evaluation, allowing researchers to quantify the impact of AI integration on cancer detection rates, recall rates, and diagnostic workflow efficiency. The pragmatic, real-world nature of the trial further ensures that findings will be directly translatable into clinical practice.

Complementing the quantitative analyses, the PRISM Trial incorporates qualitative components such as focus groups and surveys targeting both patients and radiologists. These instruments aim to capture perceptions, trust levels, and acceptance of AI in diagnostic decision-making, addressing an often-overlooked dimension in AI deployment: user and patient engagement and confidence in technology-augmented care pathways.

This trial stands as possibly the most ambitious effort yet to generate high-quality evidence on AI’s role in breast cancer screening. It is expected to inform not only clinical protocols but also insurance reimbursement policies and technology adoption strategies, as the healthcare industry grapples with integrating AI into routine care while safeguarding patient safety and optimizing outcomes.

Another pivotal aspect of PRISM is its extensive geographic and institutional reach, encompassing diverse populations and healthcare settings. This inclusivity ensures that the study evaluates AI performance across varied demographic cohorts and facility types, thereby increasing the generalizability of its conclusions and helping to identify subgroups who may derive particular benefit—or conversely, where AI assistance may not add value.

The underlying technical infrastructure supporting the trial is robust, featuring state-of-the-art AI models trained on large-scale imaging datasets and continuously updated through machine learning techniques to refine predictive accuracy. These systems operate within secure computational environments that comply with healthcare data privacy regulations, ensuring patient information confidentiality throughout the study.

The outcome of this pioneering research initiative will ultimately shed light on whether AI can reliably augment radiologists’ interpretative accuracy, reduce unnecessary recalls, and alleviate patient anxiety without compromising diagnostic safety. As Dr. Net notes, “We are poised to generate the evidence necessary to integrate AI thoughtfully, preserving the indispensable role of human expertise while harnessing the power of computational advances.”

Readouts from the PRISM Trial will offer vital guidance to clinicians, hospital administrators, policymakers, and payers as the healthcare system navigates the complex challenges and opportunities presented by AI. This trial not only pushes the boundaries of medical imaging technology but also embodies a patient-centered approach to innovation, prioritizing trust, transparency, and real-world applicability.

For ongoing updates on this and other related advancements, the Sylvester Comprehensive Cancer Center maintains a dedicated presence on their InventUM blog and social media channels, fostering open dialogue and dissemination of new knowledge to the broader scientific community and the public.

Subject of Research: Artificial intelligence in breast cancer screening and mammography interpretation

Article Title: (Not specified in the provided content)

News Publication Date: September 23, 2025

Web References:

• Sylvester Comprehensive Cancer Center: https://umiamihealth.org/en/sylvester-comprehensive-cancer-center
• InventUM blog on AI and breast cancer screening: https://news.med.miami.edu/studying-artificial-intelligence-in-breast-cancer-screening/
• Sylvester Cancer on X (formerly Twitter): https://x.com/SylvesterCancer

Image Credits: Photo by Sylvester Comprehensive Cancer Center

Keywords: Mammography, Diagnostic imaging, Breast cancer, Medical technology, Radiology